4a6l: Difference between revisions
m Protected "4a6l" [edit=sysop:move=sysop] |
No edit summary |
||
| (11 intermediate revisions by the same user not shown) | |||
| Line 1: | Line 1: | ||
==beta-tryptase inhibitor== | |||
<StructureSection load='4a6l' size='340' side='right'caption='[[4a6l]], [[Resolution|resolution]] 2.05Å' scene=''> | |||
== Structural highlights == | |||
<table><tr><td colspan='2'>[[4a6l]] is a 4 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4A6L OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=4A6L FirstGlance]. <br> | |||
</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 2.05Å</td></tr> | |||
<tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=P43:1-{3-[1-({5-[(2-FLUOROPHENYL)ETHYNYL]FURAN-2-YL}CARBONYL)PIPERIDIN-4-YL]PHENYL}METHANAMINE'>P43</scene></td></tr> | |||
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=4a6l FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4a6l OCA], [https://pdbe.org/4a6l PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=4a6l RCSB], [https://www.ebi.ac.uk/pdbsum/4a6l PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=4a6l ProSAT]</span></td></tr> | |||
</table> | |||
== Function == | |||
[https://www.uniprot.org/uniprot/TRYB2_HUMAN TRYB2_HUMAN] Tryptase is the major neutral protease present in mast cells and is secreted upon the coupled activation-degranulation response of this cell type. Has an immunoprotective role during bacterial infection. Required to efficiently combat K.pneumoniae infection (By similarity). | |||
<div style="background-color:#fffaf0;"> | |||
== Publication Abstract from PubMed == | |||
A solid phase combinatorial library was designed based on X-ray structures and in-silico models to explore an inducible S4+ pocket, which is formed by a simple side-chain rotation of Tyr95. This inducible S4+ pocket is unique to beta-tryptase and does not exist for other trypsin-like serine proteases of interest. Therefore, inhibitors utilizing this pocket have inherent advantages for being selective against other proteases in the same family. A member of this library was found to be a potent and selective beta-tryptase inhibitor with a suitable pharmacokinetic profile for further clinical evaluation. | |||
Structure-based library design and the discovery of a potent and selective mast cell beta-tryptase inhibitor as an oral therapeutic agent.,Liang G, Aldous S, Merriman G, Levell J, Pribish J, Cairns J, Chen X, Maignan S, Mathieu M, Tsay J, Sides K, Rebello S, Whitely B, Morize I, Pauls HW Bioorg Med Chem Lett. 2012 Jan 15;22(2):1049-54. Epub 2011 Dec 7. PMID:22192588<ref>PMID:22192588</ref> | |||
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | |||
</div> | |||
<div class="pdbe-citations 4a6l" style="background-color:#fffaf0;"></div> | |||
==See Also== | |||
*[[Tryptase|Tryptase]] | |||
== References == | |||
<references/> | |||
__TOC__ | |||
</StructureSection> | |||
[[Category: Homo sapiens]] | |||
[[Category: Large Structures]] | |||
[[Category: Maignan S]] | |||
[[Category: Mathieu M]] | |||
Latest revision as of 13:37, 6 November 2024
beta-tryptase inhibitorbeta-tryptase inhibitor
Structural highlights
FunctionTRYB2_HUMAN Tryptase is the major neutral protease present in mast cells and is secreted upon the coupled activation-degranulation response of this cell type. Has an immunoprotective role during bacterial infection. Required to efficiently combat K.pneumoniae infection (By similarity). Publication Abstract from PubMedA solid phase combinatorial library was designed based on X-ray structures and in-silico models to explore an inducible S4+ pocket, which is formed by a simple side-chain rotation of Tyr95. This inducible S4+ pocket is unique to beta-tryptase and does not exist for other trypsin-like serine proteases of interest. Therefore, inhibitors utilizing this pocket have inherent advantages for being selective against other proteases in the same family. A member of this library was found to be a potent and selective beta-tryptase inhibitor with a suitable pharmacokinetic profile for further clinical evaluation. Structure-based library design and the discovery of a potent and selective mast cell beta-tryptase inhibitor as an oral therapeutic agent.,Liang G, Aldous S, Merriman G, Levell J, Pribish J, Cairns J, Chen X, Maignan S, Mathieu M, Tsay J, Sides K, Rebello S, Whitely B, Morize I, Pauls HW Bioorg Med Chem Lett. 2012 Jan 15;22(2):1049-54. Epub 2011 Dec 7. PMID:22192588[1] From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine. See AlsoReferences
|
| ||||||||||||||||||